---
title: "LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286648301.md"
description: "LifeSci Capital analyst Patrick Dolezal has maintained a Buy rating on MBX Biosciences, Inc. with a price target of $91.00. The analyst has an average return of 15.0% and a 43.63% success rate. The overall analyst consensus for MBX is a Strong Buy, with an average price target of $73.11."
datetime: "2026-05-16T14:36:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286648301.md)
  - [en](https://longbridge.com/en/news/286648301.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286648301.md)
---

# LifeSci Capital Remains a Buy on MBX Biosciences, Inc. (MBX)

LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Dolezal covers the Healthcare sector, focusing on stocks such as Ibio, Neurogene, and Rocket Pharmaceuticals. According to TipRanks, Dolezal has an average return of 15.0% and a 43.63% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MBX Biosciences, Inc. with a $73.11 average price target.

### Related Stocks

- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)
- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)
- [NGNE.US](https://longbridge.com/en/quote/NGNE.US.md)
- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)
- [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md)

## Related News & Research

- [MBX Biosciences (MBX) Is Down 20.8% After Wider Loss, Obesity Data And New CCO - Has The Bull Case Changed?](https://longbridge.com/en/news/286684097.md)
- [Top MBX Biosciences Executive Makes Notable Stock Move](https://longbridge.com/en/news/285791827.md)
- [VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News](https://longbridge.com/en/news/286964504.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [Core Scientific Is Firing on All Cylinders as Analysts Approve Its Expansion Plans](https://longbridge.com/en/news/286808678.md)